『Elias Jabbour, MD / Ibrahim Aldoss, MD - ALL-in on Bispecific Innovation: Guidance on the Present and Future of Off-the-Shelf Immunotherapy in Acute Lymphoblastic Leukemia』のカバーアート

Elias Jabbour, MD / Ibrahim Aldoss, MD - ALL-in on Bispecific Innovation: Guidance on the Present and Future of Off-the-Shelf Immunotherapy in Acute Lymphoblastic Leukemia

Elias Jabbour, MD / Ibrahim Aldoss, MD - ALL-in on Bispecific Innovation: Guidance on the Present and Future of Off-the-Shelf Immunotherapy in Acute Lymphoblastic Leukemia

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/VFF865. CME/MOC credit will be available until July 4, 2026.

ALL-in on Bispecific Innovation: Guidance on the Present and Future of Off-the-Shelf Immunotherapy in Acute Lymphoblastic Leukemia

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.

Elias Jabbour, MD / Ibrahim Aldoss, MD - ALL-in on Bispecific Innovation: Guidance on the Present and Future of Off-the-Shelf Immunotherapy in Acute Lymphoblastic Leukemiaに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。